Factors Associated with Biosimilar Exclusions and Step Therapy Restrictions Among US Commercial Health Plans

Overview of attention for article published in BioDrugs, April 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
One of the highest-scoring outputs from this source (#10 of 727)
High Attention Score compared to outputs of the same age (95th percentile)
High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news: 5 news outlets
blogs: 1 blog

twitter: 15 X users

Readers on

mendeley: 5 Mendeley

Summary News Blogs X

So far, Altmetric has seen 24 X posts from 15 X users, with an upper bound of 43,908 followers.

Biosimilar drugs underused due to commercial insurance restrictions: Study @USC https://t.co/CaVKwtmYO0 https://t.co/7coX3o6EWC

22 May 2023

Reply Repost Favourite

RT @JakubHlavka: Our paper on #biosimilar coverage by commercial plans in the US published! Cancer treatment, pediatric population, and co…

05 May 2023

Reply Repost Favourite

RT @JakubHlavka: Our paper on #biosimilar coverage by commercial plans in the US published! Cancer treatment, pediatric population, and co…

05 May 2023

Reply Repost Favourite

Our paper on #biosimilar coverage by commercial plans in the US published! Cancer treatment, pediatric population, and coverage restriction of the reference products are the most significant factors associated with biosimilar coverage decisions. https://

04 May 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 20 additional X posts.